A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Inclusion criteria * Have a histologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma * With HER2 negative and PD-L1 positive tumor tissue * Have fresh or archival tumor tissue samples within 6 months for PD-L1 expression test. * Age ≥18 and ≤75 years * Diagnosed as unresectable locally advanced or metastatic stage Exclusion criteria * Have received any prior palliative systemic treatment for advanced gastric or gastroesophageal junction adenocarcinoma. * Known to have central nervous system metastases, cancerous meningitis, or bone metastases with a risk of paraplegia * Known bone metastasis with a risk of paraplegia. * Have any ascites that requires intervention. * With bilateral medium pleural effusion or unilateral large pleural effusion leading to respiratory symptoms